New Approaches to Target Bacterial Infections

A multinational pharmaceutical company is seeking new antibiotic compounds and adjuvants with antibacterial or antifungal activity or repositioned or repurposed molecules as novel therapeutics targeting multidrug-resistant bacterial pathogens. The focus is on agents that demonstrated antibacterial effects incidentally during development for unrelated indications. 

Approaches of Interest:

• Repurposing non-antibiotic drugs 
• There is significant interest in clinical indications associated with ESKAPE pathogens as well as those caused by emerging pathogens such as Candida glabrata, Candida auris, and Aspergillus fumigatus
• Combination therapies that overcome adverse effects of traditional antibiotics are preferred 
• Drugs that have advantages over traditional antibiotics specifically in resistance avoidance and safety profile

Developmental Stages of Interest:

• Opportunities from preclinical research to registration are in scope 
  • For preclinical research, small molecules will be prioritised. Peptides are of limited interest, while biologics and non-molecular approaches are out of scope 
  • For research in clinical trials and beyond, all modalities are in scope 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.